Datum | Källa | Rubrik | Typ | Alternativ |
---|---|---|---|---|
2023-07-24 | Ziccum | Ziccum säkrar andra Feasibility-avtalet på två månader: VD-intervju på svenska | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-07-20 | Ziccum | Ziccums Q2-rapport - VD-uppdatering på svenska | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-07-18 | Ziccum | ZICCUM AB (publ) Interim report Q2 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-07-17 | Ziccum | Ziccum signs Evaluation Agreement for Feasibility Study with major global Pharmaceutical Corporation | Pressreleaser | Ladda ner | Visa Stäng |
Pressreleaser |
Ziccum signs Evaluation Agreement for Feasibility Study with major global Pharmaceutical CorporationAs of today, Ziccum AB (publ) (‘Ziccum’) has signed a new Evaluation Agreement with a major global Pharmaceutical Corporation. The agreement is to perform a funded Feasibility study aiming to develop thermostable dry powder formulations in the partner mRNA/LNP projects, with a planned extension for stability testing and an option to license the LaminarPace technology. Ziccum’s new partner is one of the world’s top pharmaceutical corporations. The new agreement is for a funded Feasibility study aiming at developing dry powder versions of the partner’s mRNA/LNP materials. The formal terms of the agreement include a planned extension including stability testing, if the first step is successful, plus an option for the Pharmaceutical Corporation to negotiate a license to the LaminarPace technology. Since May 2022, Ziccum has created a substantial pipeline of new dialogues within the pharmaceutical industry. In parallel the company strengthened its focus on mRNA in lipid nanoparticles (LNPs), with proof of drying mRNA/LNP materials with well-preserved vaccine activity in March 2023. mRNA in LNP formulation is the vaccine technology that was key to the rapid development of Covid-19 vaccines and is currently one of the most fast-developing fields within pharmaceutical development world-wide. During spring, CEO Ann Gidner has presented the Ziccum mRNA/LNP capabilities and findings, fueling industry interest, at several international summits and conferences. This is the second agreement Ziccum has signed with a leading global pharmaceutical corporation in just over two months, thanks to the significant scientific and commercial progress the company has made based on new strategy and new leadership. The agreement signing is a milestone achievement in Ziccum’s Project Portfolio. The current project is expected to commence in July 2023 and the first stage will run for a number of months. Both parties will be evaluating the properties of the resulting materials. CEO Ann Gidner: “The Ziccum team is certainly excited to begin this important and well-designed project in such a valuable field. Partnering up with this high caliber Pharma Corporation is an honor for us, and it brings significant future business potential. Hopefully generating excellent results, this collaboration can enable important advantages in the development of mRNA/LNP treatments for our partner.” |
||||
2023-06-19 | Ziccum | Ziccum sponsors the Global mRNA-Based Therapeutics Summit, Boston MA, July 26-28 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-05 | Ziccum | Ziccum joint proposal not selected for detailed application in current CEPI Call | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-02 | Ziccum | Ziccum appoints senior biopharma executive as new CFO | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-30 | Ziccum | Ziccum AB: BioStock Life Science Spring Summit med Ziccum | Pressreleaser | Visa Stäng |
|
||||
2023-05-30 | Ziccum | Ziccum AB: BioStock Life Science Spring Summit with Ziccum | Pressreleaser | Visa Stäng |
|
||||
2023-05-26 | Ziccum | Aerosol and inhalation authority Per Gerde joins Board of Directors of Ziccum AB | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-25 | Ziccum | Ziccum CEO to present at BioStock Life Science Spring Summit | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-24 | Ziccum | Kommuniké från årsstämma i Ziccum AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-24 | Ziccum | Bulletin from the Annual General Meeting of Ziccum AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-11 | Ziccum | Strategin ger resultat med betald studie i samarbete med toppbolag: VD-intervju på svenska | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-09 | Ziccum | Ziccum signs Evaluation Agreement with Biopharmaceutical Corporation focused on mRNA technologies | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-09 | Ziccum | Ziccums Q1-resultat: VD-uppdatering på svenska | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-08 | Ziccum | KOMPLETTERING TILL KALLELSEN TILL ÅRSSTÄMMA I ZICCUM AB (PUBL), ATT HÅLLAS DEN 24 MAJ 2023, KL. 11.00 I BOLAGETS LOKALER PÅ SCHEELEVÄGEN 22 I LUND | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-02 | Ziccum | Ziccum AB filing three patent applications as part of new, expanded strategy to strengthen patent protection | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-04-26 | Ziccum | ZICCUM AB (publ) releases Interim report Q1 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-04-24 | Ziccum | KALLELSE TILL ÅRSSTÄMMA I ZICCUM AB (PUBL) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-03-20 | Ziccum | Ziccum reports positive results from drying of active mRNA and promising mRNA activity after powder reconstitution | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-03-17 | Ziccum | Ziccum to attend BIO-Europe Spring in Basel | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-03-10 | Ziccum | Ziccum AB joins innovative financial platform for Investor Relations management and European outreach | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-02-17 | Ziccum | ZICCUM AB (publ) releases Annual Report 2022 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-01-27 | Ziccum | ZICCUM AB (publ) Year-end report Q4 2022 | Analyser | Ladda ner | Visa Stäng |
|
||||
2023-01-23 | Ziccum | Ziccum submits Expression of Interest for CEPI funding | Analyser | Ladda ner | Visa Stäng |
|
||||
2023-01-18 | Ziccum | Ziccum CEO to present at international mRNA Summit in Berlin | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-12-16 | Ziccum | Ziccum awarded 10 MSEK Eurostars funding for 3D-modeling and Digital twin project | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-12-14 | Ziccum | Ziccum launches new, expanded website | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-12-08 | Ziccum | Ziccum signs agreement with Zurich University of Applied Sciences on advanced 3D-modeling project | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-10-28 | Ziccum | Ziccums Q3-resultat: VD-uppdatering på svenska | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-10-27 | Ziccum | ZICCUM AB (publ) Interim report Q3 2022 | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-10-24 | Ziccum | Ziccum generates proof of successful drying of lipid nanoparticles in mRNA project | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-09-27 | Ziccum | Ziccum reopens application for CEPI funding on thermostable vaccines with new partner | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-09-23 | Ziccum | Ziccum receives results from evaluation study with leading Pharmaceutical Corporation | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-09-14 | Ziccum | Ziccum and Zurich University of Applied Sciences submit joint application for Eurostars funding | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-09-01 | Ziccum | Ziccum on the move: company to attend major industry events across Europe in 2022 | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-08-23 | Ziccum | ZICCUM AB (publ) Interim report Q2 2022 | Analyser | Ladda ner | Visa Stäng |
|